Biotechnology

Challenge: Innovative Medical Countermeasures: Next-Generation Influenza Vaccines by HaDEA

  Speed up the Development of and Access to Innovative Medical Countermeasures: Next-Generation Influenza Vaccines Health and Digital Executive Agency (HaDEA) About The Health and Digital Executive Agency (HaDEA) addresses the European Commission’s ambition to help rebuild a post-COVID-19 Europe at its heart, which will be greener, more digital and more resilient. It has launched a call for tenders of an estimated budget of €225 000 000 under the EU4Health Programme.  This call will be implemented in three distinct phases. The Challenge The challenge focuses on accelerating the development of next-generation influenza vaccines that can be rapidly produced, broadly protective, and adaptable to emerging pandemic threats. A key objective is to develop vaccine candidates that are either intrinsically immunogenic or effective without the need for adjuvants, thus simplifying formulation and potentially accelerating regulatory pathways. By fostering such innovations, the procurement aims to strengthen pandemic preparedness and reduce reliance on slower, conventional vaccine platforms, positioning Europe at the forefront of resilient and responsive immunisation strategies. Timeframe Interested parties are invited to apply via the Funding and Tenders Portal by May 19h, 2025, 15:00 (UTC+2) Eastern European Time, Central European Summer Time Who can apply The tender is open to small and medium-sized enterprises (SMEs), as well as other entities, as as specified in the procedure's descriptive document. How to apply You can find all the details of the procedure here.     The SPIN4EIC consortium is not responsible for the challenges launched by private or public buyers. Each participating entity is solely responsible for its own challenge, including the selection process, communication with applicants, and all information provided to participants. 

Challenge: Minimally invasive detection of micronutrient levels in humans by Haleon

Minimally invasive detection of micronutrient levels in humans Haleon About Haleon is a global consumer health company based in the United Kingdom, with deep expertise in science-led innovation across oral health, pain relief, respiratory, digestive health, and vitamins.  The Challenge The challenge focuses on developing a cost-effective, minimally invasive solution to assess micronutrient levels in humans, designed for at-home or on-site use and capable of delivering quick and reliable results, such as saliva-based assays, low-volume blood tests, or spectroscopy-based tools, among others.  It aims to: 

• Enable minimally invasive, user-friendly testing with rapid results 

• Provide accurate and reliable micronutrient assessment 

• Deliver low-cost, scalable solutions suitable for mass-market and at-home use 

• Leverage innovative technologies adapted for consumer or retail applications 

Reward  Successful applicants can receive a 6-month funded project, ranging from $25,000 to $100,000, including access to Haleon’s technical experts and the potential for ongoing collaboration and partnership development.  Timeframe Deadline for Submitting Offers: April 30h, 2025. Who can apply Applicants with TRL 2-9 solutions  How to apply Application through HALO Platform.  Find here all the details and the submission page.  The SPIN4EIC consortium is not responsible for the challenges launched by private or public buyers. Each participating entity is solely responsible for its own challenge, including the selection process, communication with applicants, and all information provided to participants.